Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OpTcells
- Development stage
- Preclinical
- Lead developer
- Peaches Biotech
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
OpTcells (Organoid Primed T Cells) is an autologous adoptive cell therapy (ACT) developed by Peaches Biotech in collaboration with Harvard Medical School for the treatment of pancreatic ductal adenocarcinoma (PDAC). The therapeutic process involves a personalized approach where a patient's own lymphocytes are "educated" or primed through co-culture with three-dimensional organoids generated from the patient's own tumor cells. This priming step, based on technology licensed from Beth Israel Deaconess Medical Center (BIDMC), is designed to activate and expand tumor-specific T cells that can then be re-infused into the patient to target and eliminate cancer cells. The approach aims to provide a paradigm shift in treating highly fatal diseases like PDAC by potentially preventing recurrence through a directed cellular immune response. The program is currently in preclinical development.
- Other names
- OpT cellsOrganoid Primed T Cells
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on OpTcells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OpTcells.